Business Description
VERAXA Biotech AG is a German biotech company founded in 2021 and headquartered in Heidelberg, specializing in the development of targeted cancer therapies. The company builds antibody-based treatments, including antibody-drug conjugates and bispecific formats, supported by its own technology platform for antibody screening and precise drug attachment. VERAXA partners with organizations across the life sciences and healthcare sectors, offering collaborative development services ranging from early target identification through to finished therapeutic candidates, while also licensing its platform technologies to others pursuing new treatment approaches.
